Cross-reactivity of nefopam and its metabolites with benzodiazepine EMIT immunoassay

Journal of Analytical Toxicology

Volumn 32, Issue 9, 2008, Pages 790-792

  El Haj, Babiker ^a   Al Amri, Abdulkader ^a   Ali, Heyam ^b  

^a Sharjah Police Forensic Sci Lab   (United Arab Emirates)

^b DUBAI PHARMACY COLLEGE   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; DESMETHYLNEFOPAM; DESMETHYLNEFOPAM GLUCURONIDE; DRUG METABOLITE; NEFOPAM; OXAPROZIN; OXAZEPAM; UNCLASSIFIED DRUG; ANALGESIC AGENT; BENZODIAZEPINE DERIVATIVE;

CROSS REACTION; DEMETHYLATION; DRUG EXCRETION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; HUMAN; HYDROGEN BOND; LETTER; MASS FRAGMENTOGRAPHY; URINALYSIS;

ANALGESICS, NON-NARCOTIC; BENZODIAZEPINES; CROSS REACTIONS; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; NEFOPAM;

EID: 57349143738     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/32.9.790     Document Type: Letter

References (24)

1. Dade Behring. EMIT d.a.u. and EMIT II Plus reagents inserts.
2. K.E. Moeller, K.C. Lee, and J.C. Kissack. Urine drug screening: practical guide for clinicians. Mayo Clin. Proc. 83: 66-76 (2008).
3. K.L. Kelly. Ranitidine cross-reactivity in the EMIT dau monoclonal amphetamine/methamphetamine assay. Clin. Chem. 36: 1391-1392 (1990).
4. A. Poklis, K.V. Hall, J. Still, and S.R. Binder. Ranitidine interference with the monoclonal EMIT d.a.u. amphetamine/methamphetamine immunoassay. J. Anal. Toxicol. 15: 101-103 (1991).
5. K.M. Olsen, M. Gulliksen, and A.S. Christophersen. Metabolites of chlorpromazine and bromipheniramine may cause false-positive urine amphetamine results with monoclonal EMIT dau immunoassay. Clin. Chem. 38: 611-612 (1992).
6. M. De Paula, L.C. Saiz, J. Gonzalez-Revalderia, T. Pascual, C. Alberola, and E. Miravalles. Rifampicin causes false-positive immunoassay results for urine opiates. Clin. Chem. Lab. Med. 36: 241-243 (1998).
7. H. Van As and L.M.L. Stolk. Rifampicin cross-reacts with opiate immunoassay. J. Anal. Toxicol. 23: 71 (1999).
8. R. Daher, J.H. Haidar, and H. Al-Amin. Rifampicin interference with opiate immunoassays. Clin. Chem. 48: 203-204 (2002).
9. L.R. Baden, G. Horowitz, H. Jacoby, and G.M. Eliopoulos. Quinolones and false-positive urine screening for opiates by immunoassay technology. J. Am. Med. Assoc. 286: 3115-3116 (2001)
10. C.M. Straley, E.J. Cecil, and M.P. Harriman. Gatifloxacin interference with opiate urine drug screen. Pharmacotherapy 26: 435-439 (2006).
11. P.D. Camara, L. Audette, K. Velletri, P. Breitenbecher, M. Rosner, and W.C. Griffiths. False-positive immunoassay results for urine benzodiazepine in patients receiving oxaprozin (Daypro). Clin. Chem. 41: 115-116 (1995).
12. A.D. Fraser and P. Powell. Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepine in urine. J. Anal. Toxicol. 22: 50-54 (1998).
13. P. Moorman, M. McCoy, B. Hague, and D. Huge. Disopyramide cross-reactivity in a commercial immunoassay reagent for methadone. J. Anal. Toxicol. 23: 299-300 (1999).
14. S.F. Sena, S. Kazim, and A.H.B. Wu. False-positive phencyclidine immunoassay results caused by venlafaxine and O-desmethylvenlafaxine. Clin. Chem. 48: 676-677 (2002).
15. C.J. la Porte, J.A. Droste, and D.M. Burger. False-positive results in urine drug screening in healthy volunteers participating in phase 1 studies with efavirenz and rifampin. Ther. Drug Monit. 28: 286 (2006).
16. K.S. Siff and A.E. Finkler. False-positive barbiturate test in urine owing to phenytoin and 5-(p-hydroxyphenyl)-5-phenylhydantoin. Clin. Chem. 34: 1359-1360 (1988).
17. D.E. Rollins, T.A. Jennison, and G. Jones. Investigation of interference by nonsteroidal anti-inflammatory drugs in urine tests for abused drugs. Clin. Chem. 36: 602-606 (1990).
18. C.E. Cook. Critical overview on immunological and chromatographic analytical methods. In First International Symposium on Current Issues of Drug Abuse Testing, J. Segura and R. de la Torre, Eds. CRC Press, London, U.K., 1992, p 79.
19. D.M. Piercy, J.A. Cumming, S. Dawling, and J.A. Henry. Death due to overdose of nefopam. Br. Med. J. 283: 1508-1509 (1981).
20. S.C. Urwin and H.S. Smith. Fatal nefopam overdose. Br. J. Anaesth. 83: 501-502 (1999).
21. A. Tracqui, L. Berthelon, and B. Ludes. Fatal overdosage with nefopam (Acupan). J. Anal. Toxicol. 26: 239-243 (2002).
22. Clarke's Analysis of Drugs and Poisons, Vol. 2, 3rd ed., A.C. Moffat, M.D. Osselton, and B. Widdop, Eds. The Pharmaceutical Press, London, U.K., 2004, pp 1325-1326.
23. D.J. Newman and C.P. Price. Molecular aspects of design of immunoassays for drugs. Ther. Drug Monit. 18: 493-497 (1996).
24. Martindale. The Complete Drug Reference, 33rd ed., S.C. Sweetman, Ed. The Pharmaceutical Press, London, U.K., 2002, p 62.